Comparative Pharmacology
Head-to-head clinical analysis: HYDROXYZINE HYDROCHLORIDE versus PROMETHAZINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROXYZINE HYDROCHLORIDE versus PROMETHAZINE HYDROCHLORIDE.
HYDROXYZINE HYDROCHLORIDE vs PROMETHAZINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydroxyzine hydrochloride is a first-generation antihistamine that acts as a competitive antagonist at histamine H1 receptors. It also possesses anticholinergic, antiemetic, and sedative properties. Its mechanism involves binding to H1 receptors in the gastrointestinal tract, uterus, blood vessels, and bronchial muscles, thereby inhibiting histamine-mediated effects.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, blocking the effects of histamine at H1 receptors. It also has anticholinergic, antiemetic, sedative, and antidopaminergic properties.
25-100 mg orally or intramuscularly 3-4 times daily; maximum 600 mg/day.
25-50 mg intramuscular or intravenous injection every 4-6 hours as needed; also 12.5-25 mg orally every 4-6 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 20-25 hours in adults. In elderly or hepatic impairment, may be prolonged. Clinical context: Achieves steady-state after ~4-5 days; detectable for >72 hours after cessation.
Terminal elimination half-life is 10-19 hours in adults; prolonged in hepatic impairment (up to 30+ hours) and in elderly.
Primarily hepatic metabolism via CYP3A4 and CYP3A5; <1% excreted unchanged in urine. Renal elimination of metabolites (approx. 50-60% of total clearance), with minor fecal excretion (<10%).
Primarily hepatic metabolism; renal excretion of metabolites accounts for <1% of unchanged drug; biliary/fecal excretion of metabolites ~70-80%.
Category A/B
Category A/B
Antihistamine
Antihistamine / Antiemetic